- 1 COMPARATIVE ANALYSIS OF ANTIBODY RESPONSES FROM COVID-19 CONVALESCENTS RECEIVING
- 2 VARIOUS VACCINES REVEALS CONSISTENT HIGH NEUTRALIZING ACTIVITY FOR SARS-CoV-2
- 3 VARIANT OF CONCERN OMICRON.
- 4
- 5 Daniele Focosi<sup>1,#</sup>, Massimo Franchini<sup>2</sup>, Michael J. Joyner<sup>3</sup>, Arturo Casadevall<sup>4</sup>
- <sup>1</sup>North-Western Tuscany Blood Bank, Pisa University Hospital, 56124 Pisa, Italy.
- 7 <sup>2</sup>Division of Transfusion Medicine, Carlo Poma Hospital, 46100 Mantua, Italy;
- 8 <u>massimo.franchini@asst-mantova.it</u>
- <sup>3</sup> Department of Anesthesiology & Perioperative Medicine, Mayo Clinic, Rochester, MN 55902, USA
- 10 joyner.michael@mayo.edu;
- <sup>3</sup>Department of Medicine, Johns Hopkins School of Public Health and School of Medicine, Baltimore,
- 12 MD 21218, USA; acasade1@jhu.edu .
- 13 <sup>#</sup>corresponding author: via Paradisa 2, 56124 Pisa, Italy. E-mail: <u>daniele.focosi@gmail.com</u>
- 14 Keywords: COVID19; Omicron; convalescent plasma; vaccine; neutralizing antibodies; outpatients.
- 15 Word count: abstract 101; body 1478.
- 16 Acknowledgements: none.
- 17 **Funding Information**: none.
- 18 Author contributions: D.F. and M.J.J. conceived the manuscript; D.F. and M.F. analyzed the
- 19 literature; M.F. provided Figure 1; D.F. provided Figure 2; A.C. and M.J.J. revised the manuscript.
- 20
- 21

#### 22 Abstract

23 The novel SARS-CoV-2 Omicron variant of concern (VOCs), with its escape from unboosted vaccines 24 and monoclonal antibodies, demonstrates the continued relevance of COVID19 convalescent plasma 25 therapies. Lessons learnt from previous usage of CCP suggests focusing on outpatients and using 26 high nAb-titer units in early disease stages. In this systematic analysis, we show that CCP from 27 unvaccinated donors is not effective against Omicron, while CCP from vaccinees convalescents from 28 previous VOCs or third-dose uninfected vaccinees is likely to remain effective against Omicron. CCP 29 remains the only antibody-based therapy that keeps up with the variants and provides an effective 30 tool to combat the emergence of variants that defeat monoclonal antibodies. Consequently, there is 31 a need for continue study of the variables that determine CCP efficacy.

#### 33 Introduction

34 The SARS-CoV-2 Omicron variant of concern (VOC), named VUI-21NOV-01 by Public Health England 35 and belonging to GISAID clade GR/484A, was first reported on November 8, 2021 in South Africa 36 (particularly in Gauteng, North West and Limpopo regions, where it is likely to have been circulating 37 for weeks [1]), and shortly thereafter spread all around the world. Omicron mutations impact 27% of 38 T cell epitopes [2] and 31% of B cell epitopes of Spike, while percentages for other VOC were 39 significantly lower [3]. The omicron variant already includes several sublineages (with more expected 40 soon during such a massive spread), which are named by PANGO phylogeny using the BA alias: BA.1 (which represents the majority of cases) and BA.3 (a.k.a. 21K in NextStrain, both harboring the 41 42 HV69-70 deletion which leads to S-gene target failure in Thermo Fisher TaqPath® RT-PCR), and BA.2 43 (a.k.a. 21L in NextStrain).

44 The novel VOC Omicron is reducing the efficacy of all vaccines approved to date (unless 3 doses are 45 delivered) [4-19], represents an unexpected boost over CCP usage, with Omicron being treated as an 46 entirely novel virus instead of a SARS-CoV-2 variants. Two years into the pandemics, we are back to 47 the starting line for some therapeutic agents. Importantly, Omicron evades most monoclonal 48 antibodies (mAbs) approved to date [5,12-14,20,21] with the lone exception of sotrovimab: 49 nevertheless, as expected for non-cocktail mAb therapies, sotrovimab treatment-emergent immune 50 escape from S:E340K has been shown to be as high as 10% [22,23]. Despite the development of 51 promising oral small-chemical antivirals (molnupiravir and nirmatrelvir), the logistical and 52 economical hurdles for deploying these drugs worldwide will prevent their immediate availability. 53 COVID19 convalescent plasma (CCP) was used as a frontline treatment from the very beginning of 54 the pandemic. Efficacy outcomes have been mixed to date, with most failures explained by low dose 55 and late usage [24], but efficacy of high-titer CCP has been definitively proven in outpatients with 56 mild disease stages [25,26]. Neutralizing antibody (nAb) efficacy against variants of concerns (VOC) 57 remains a prerequisite to support CCP usage, which could now be collected also from vaccinated 58 convalescents including breakthrough infections [27]: pre-Omicron evidences suggest that those 59 nAbs have higher titers and are more effective against VOCs than those from unvaccinated 60 convalescents [28,29],

61 Several countries have up to 48 different possible vaccine schedules according to EMA and FDA 62 approvals including a number of homologous or heterologous boosts, but the most commonly 63 delivered in the westernized countries were 1) BNT162b2 and mRNA-1273 for 2 doses eventually 64 followed by a homologous boost; 2) ChAdOx1 for 2 doses eventually followed by a BNT162b2 boost; 65 3) Ad26.COV2.S for 1 dose eventually followed by a BNT162b2 boost. Many more inactivated 66 vaccines have been in use in low-and-middle income countries, the ideal target regions for CCP 67 therapy, widen that this therapy is relatively inexpensive. All these patients can have received the 68 vaccine schedule before, after or without having been infected, and, further complicating the 69 picture, the nAb titer generally declines with time. Hence identifying the settings where the nAb titer 70 is highest will definitively increase the appropriateness of CCP collections. Variations in nAb titers against a given SARS-CoV-2 strain are usually reported as fold-changes in geometric mean titer 71 72 (GMT) compared to wild-type strains: nevertheless, fold-changes for groups that include non-73 responders can lead to highly artificial results and possibly over-interpretation. Rigorous studies 74 have hence reported the percentage of responders as primary outcome and provided fold-changes 75 of GMT where calculation is reasonable (100% responders in both arms) [19].

To date the most rigorous data repository for SARS-CoV-2 sensitivity to antivirals is the Stanford
University Coronavirus Antiviral & Resistance Database, but as of December 22, 2021 the tables
there summarizing "Virus Variants and Spike Mutations vs Convalescent Plasma"

79 (https://covdb.stanford.edu/page/susceptibility-data/#:~:text=Table%202.-

- 80 ,Virus%20Variants%20and%20Spike%20Mutations%20vs%20Convalescent%20Plasma,-
- 81 <u>Table%203.%20Virus</u>) and "Virus Variants and Spike Mutations vs Plasma from Vaccinated Persons"
- 82 (https://covdb.stanford.edu/page/susceptibility-
- 83 <u>data/#table.2.virus.variants.and.spike.mutations.vs.convalescent.plasma</u>) report aggregate data

84 from only 6 studies, and do not dissect the infecting sublineages, nor the different heterologous or

85 homologous vaccination schemes, nor the time from infection/vaccine to neutralization assay.

- 86 Consequently, a more in-depth analysis is needed to better stratify the populations.
- 87

# 88 Methods

On December 22, 2021, we searched PubMed, medRxiv and bioRxiv for research investigating the efficacy of COVID19 convalescent plasma (either from vaccinated or unvaccinated donors) against SARS-CoV-2 VOC Omicron. In unvaccinated patients, convalescence was annotated according to infecting sublineage (unspecified, D614G wild-type, VOC Alpha, VOC Beta or VOC Delta). Given the heterologous immunity that develops after vaccination in convalescents, the infecting lineage was not annotated in vaccine recipients. In vaccinees, strata were created for uninfected, 1 dose, 2 hemelogous doses 2 hemelogous doses or heterologous combinations.

95 homologous doses, 3 homologous doses, or heterologous combinations.

96

### 97 **Results**

Figure 1 shows the PRISMA flowchart for this study. Our literature search identified 22 studies, thatwere then manually mined for relevant details.

Given the urgency to assess efficacy against the upcoming VOC Omicron, most studies (with a few exceptions [21,30]) relied over Omicron pseudovirus development and neutralization assays, which, as opposed to live authentic virus, are scalable, do not require BSL-3 facilities, and provide results in less than 1 week.

Table 1 shows that CCP collected from unvaccinated convalescents (regardless of the infecting
lineage) harbors very low or no neutralizing activity against Omicron, and are hence clinically
useless.

Table 2 shows that CCP from vaccinees that have not been previously or later infected has very low nAb content against Omicron. On the other hand, CCP collected from vaccinated convalescents is generally high in nAb content against Omicron, regardless of the order of events (infection/vaccination vs. vaccination/breakthrough infection [31]), of the infecting sublineage, and of the number of vaccine doses.

112

### 113 Discussion

Although nAb titers correlate with vaccine efficacy [32,33], it is important to keep in mind that SARS-CoV-2 binding non-neutralizing antibodies can similarly provide protection via Fc-mediated functions [34,35]. However, these are harder to measure in the laboratory and no automated assay exist for use in clinical laboratories. Hence, whereas the presence of a high nAb titer in CCP is evidence for antibody effectiveness *in vitro*, the absence of nAb titer does not imply lack of protection *in vivo* where Fc effects mediate protection by other mechanisms such as ADCC, complement activation and

phagocytosis. That said, it is always preferable to use CCP with a high nAb titer since that is positive
correlate for antiviral activity and there is now strong clinical evidence that such titers correlate with
efficacy in clinical trials [25,26].

123 This systematic review provides strong evidence that CCP from unvaccinated donors is unlikely to be 124 effective against Omicron. On the contrary, despite the huge heterogeneity of vaccine schedules, 125 CCP from vaccinated COVID-19 convalescent individuals consistently harbors high nAb titers against 126 Omicron if collected up to 6 months since last event (either vaccine dosage or infection). 127 Consequently, prescreening of CCP donors for nAb titers is not necessary, and qualification of CCP 128 units remains advisable only within clinical trials. A more objective way to assess previous infection 129 would be measuring anti-nucleocapsid (N) antibodies, but unfortunately these vanish quickly [36,37]. 130 Previous symptomatic infection and vaccination can be established by collecting past medical history 131 (PMH) during the donor selection visit, which is cheaper, faster, and more reliable than measuring 132 rapidly declining anti-N antibodies. Although there is no formal evidence for this, it is likely that 133 asymptomatic infection (leading to lower nAb levels) also leads to lower nAb levels after vaccination 134 compared to symptomatic infection, given that disease severity correlates with antibody titer 135 [38,39]: hence those asymptomatically infected donors missed by investigating PMH are less likely to 136 be useful.

137 The same reasoning applies to uninfected vaccinees receiving third dose boosts, but several 138 authorities, including FDA, do not allow collection from such donors for CCP therapy on the basis 139 that the convalescent polyclonal and poly-target response is a prerequisite for efficacy and superior 140 to the polyclonal anti-Spike only response of vaccinees. This may be a false premise for recipients of 141 inactivated whole-virus vaccines (e.g., BBIBP-CorV or VLA2001): for BBIBP-CorV, the efficacy against 142 Omicron is largely reduced [40,41], but the impact of boost doses is still unreported at the time of 143 writing. For CoronaVac<sup>®</sup> (SinoVac), three doses led to 5.1 fold-reduction in nAb titer [41], while for 144 Sputnik V nAb titer moved from a 12-fold reduction at 6-12 months up to a 7-fold reduction at 2-3 145 months after a boost with Sputnik Light [30].

Another point to consider is that information on levels after third dose do not currently exceed more than one month of follow-up, while studies on convalescents extend to more than 6 months: to date it seems hence advisable to start from convalescent vaccinees rather than uninfected 3-dose vaccinees. Vaccine schedules with a delayed boost seem to elicit higher and broader nAb levels than the approved, short schedules [42-45], but this remain to be confirmed in larger series.

With the increase of Omicron seroprevalence in time, polyclonal intravenous immunoglobulins collected from regular donors could become a more standardized alternative to CCP (see Figure 2), but their efficacy to date (at the peak of the vaccinations campaign) is still 16-fold reduced against Omicron compared to wild-type SARS-CoV-2 [14], and such preparations include only IgG and not IgM and IgA, which have powerful SARS-CoV-2 activity.

156 CCP collection from vaccinated convalescents (regardless of infecting sublineage, vaccine type and 157 number of doses) is likely to achieve high nAb titer against VOC Omicron, and, on the basis of lessons 158 learnt with CCP usage during the first 2 years of the pandemic. Although in ideal situations one 159 would prefer RCT evidence of efficacy against omicron before deployment there is concern that 160 variants are generated so rapidly that by the time such trials commenced this variant could be 161 replaced for another. Given the success of CCP in 2 outpatient RCTs reducing hospitalization [25,26] 162 and the loss of major mAb therapies due to Omicron antigenic changes, the high titers in CCP 163 collected from vaccinated convalescents provides an immediate option for COVID-19, especially in 164 resource poor areas. Given the reduced hospitalization rate with Omicron compared to Delta

165 [46,47], it is even more relevant to identify patient subsets at risk of progression in order to minimize

166 the number needed to treat to prevent a single hospitalization: moving from the same criteria used

167 for mAb therapies while using the same (now unused) in-hospital facilities seems a logical approach.

168	We	declare	we	have	no	conflict	of	interest	related	to	this	manuscript.
-----	----	---------	----	------	----	----------	----	----------	---------	----	------	-------------

# 169 Table 1

170 Efficacy of CCP collected from unvaccinated COVID19 survivors, infected from different SARS-CoV-2 VOC, against VOC Omicron. Efficacy is reported as

171 ED<sub>50</sub>/IC<sub>50</sub> or fold-reductions (FR) compared to wild-type D614G lineages (e.g. USA-WA1/2020) at different time points since onset of symptoms or positivity,

expressed in days (d) or months (m). BAU: binding arbitrary unit. LOD: limit of dilution.

	convalescents from VOC										
unspecified	D614G	Alpha	Beta	Delta							
	no activity @ 1.5 and 12m				Gruell [48]						
	ID <sub>50</sub> < 135 @ 1m				Liu [13]						
	21 FR, all < LOD (1:20)				Aggarwal [14]						
		47 FR		17 FR	Ikemura [8]						
	80 FR @ 2m				Hoffman [49]						
	BAU/ml reduced from 3x10 <sup>3</sup> to 8x10 <sup>2</sup> at 7-25 days (n = 27)				Schubert [11]						
none at 6m and 12m					Planas [12]						
(36 pts)											
58 FR @ 1.3m					Schmidt [50]						
32 FR @ 6.2m											
	ED <sub>50</sub> 68 (10.6 FR @ 1 mo), 65 (5.1 FR @ 3 mo)				Zhang [51]						
		C <sub>50</sub> < 1:16 in 0/10 pts	IC <sub>50</sub> < 1:16 in 7/8 pts	IC <sub>50</sub> < 1:16 in 6/7 pts	Rossler [15]						
17 FR					Zhao [41]						
	none (2/9 of ICU and 1/9 of hospitalized above cutoff)			none (0/12)	Zeng [17]						
	40 FR ( C <sub>50</sub> 23.4  U/m ) @ 1m or 4m				Sheward [18]						
				28.9 FR	Lechmere [31]						
none in 73.3%					Carreno [21]						
	15 FR @ 1 m 4.4 FR @ 6 m				Zou [52]						
	2/20 pts, 2.3-70.1 FR @	2/5 pts, 2.3-70.1 FR	2/2 pts, 2.3-70.1 FR @ 1m	15/17 pts, 22.1-74.4 FR @ 1m	Lusvarghi [53]						

	1m	@ 1m		
IC <sub>50</sub> 15-18 at ? mo				Syed [54]

#### 174 Table 2

- 175 Efficacy against VOC Omicron of convalescent plasma collected from vaccinated donors, either infected (either before, between or after vaccination with 1
- 176 or more homologous or heterologous doses) or uninfected (with 3 homologous or heterologous doses), reported as NT<sub>50</sub>/ED<sub>50</sub>/IC<sub>50</sub> (dilution factors that
- 177 yields 50% neutralization of SARS-CoV-2) or fold-reduction (FR) in nAb titers compared to wild-type D614G lineage. Time after last event (infection or
- vaccination) is reported when available from the original source. The single reference for CoronaVax and Sputnik V are both discussed within the text for
- 179 space constraints.

B	BNT162b2/tozinameran (Comirnaty®) (Pfizer/BioNtech)					RNA-1273	/elasomeran (Moderna)	(Spikeva	X®)	AZ	D1222 / Ch Covishield <sup>e</sup>	AdOx1 (Vax ®) (AstraZer	zevria®, ieca)	JNJ-78436735/ Ad26.COV2.S® (J&J/Janssen)		ref
2 doses	3 doses	convale scent + 1 dose	convale scent + 2 doses	convale scent + 3 doses	2 doses	3 doses	2 doses + BNT162b 2	2 doses + infecti	3 doses + infecti	2 doses	2 dose + infectio n	1 dose + BNT162 b2	1 dose + 2 BNT162bd oses	1 dose	1 dose + BNT162 b2	-
11.4 FR @ 6 m	10 at 0.5 m, (8 FR); 0 @ 3m (20 FR)		32.8-FR @ 1-7m		0 (20 FR comp ared to Delta) @ 6m		22.7 FR @ 0.5m 20 FR @ 6m					10 FR compar ed to Delta @ 6m	27.1 FR compared to Delta @ 0.5m			Wilhelhm [4]
>6.0FR @ 1m	>4.1 FR @ 1m	ID <sub>50</sub> 1,549 @ 1m			>6.0F R @ 1m	>4.1FR @ 1m										Gruell [48]
														ID <sub>50</sub> < 153 @ 1m		Liu [13]
			17.9- 26.6 FR					17.9- 26.6 FR								Aggarwal [14]
					27 FR @ 3m											lkemura [8]
34 FR @ 3m						8 FR @ 1m						14 FR @ 1m				Hoffman [49]
			4.5 FR @ 12-								4.5 FR @ 12-					Lechmere [31]

			22d							22d				
			after							Delta				
			Delta							BTI				
			BTI											
BAU/m	BAU/m												BAU/m	Schubert
reduced	minimall												minimall	[11]
from	У												У	
3x10° to	reduced												reduced	
8x10 <sup>2</sup> @	@ 5-49d												@ 5-49d	
7-25d (n														
= 27)														
none @	ED <sub>50</sub> of	ED <sub>50</sub> of							none					Planas [12]
5m	1050@	1598 @							@ 5m					
107 50		IM	NT	107		NT 2071						NT .		C alt and ide
127 FR	NI <sub>50</sub>		NI 50 8106	12/		$NI_{50} 3871$						NI 50 <		Schmidt
	50/1@		0100	1 2m		۳ III						∠5 @ ~1m		[50]
5m	±111		folds	27 FR								and 13		
5111			increase	@ 5m								@ 5m		
			compare	esin								esin		
			d to											
			prevacci											
			nation)											
	22 FR	22 FR @												Cele [6]
	@ 10-60	10-60 d												
	d													
				49-84	4.2-6.5		? in 2							Doria-Rose
				FR @	FR @		pts							[55]
				1m	2w		infect							
					after		ed							
					50 µg		betwe							
					boost		en							
							dose							
							2 and							
							3							
$ C_{50}  < 1.1C$ in		$ C_{50}  < 1.1C$ in		IC <sub>50</sub> <					$ C_{50}  < 1.1c$		$ C_{50}>$			Rossier
11/20		1/5+-		1:16					1:10		1:10 IN			[15]
11/20		1/5 pts		0/10							//20 pts			
μις		od first		9/10					20/20 nts					
		eamst		pts				1	pts				1	

		and 0/5													
		infected													
		first													
		IIISL													
22.9 FR	3.3 FR				22.9	3.3 FR								Z	Zeng [17]
@ 1m	@ 1-				FR @	@ 1-									
(20 pts)	11w (23				1m	11w									
	pts)				(28	(23									
	. ,				nts)	nts)									
22 ED	7 5 50		14 ED	12 ED	4.2 EP	16.7		11 ED						(	Carrono
23 FN	7.3 FN		14 FN	13 FN	42 FN	10.7		TTLV							
						FK									[21]
15-18 FR					15-18									9	Syed [54]
					FR										
none @			22 FR @	14 FR @	none			22 FR	14-FR					F	Edara [56]
6m			6m	< 1 m	@ 6m			@ 6m	@ <						
om			om	<b>1</b>	e on			e oni	1m						
									TIII						
16W			@ 3w											0	Chatterjee
apart: @			@4m											[	[42]
3w			(10 pts)												
@ 4m															
(10 pts)															
4w															
anart: @															
apart. @															
3W															
@ 4m															
(12 pts)															
only in	In29/29													L	Lusvarghi
5/29	nts													l I	[52]
5/25	21.0													1	[55]
pt3. 25.5	51.0-														
FRat	Told														
1m	increase														
1	@ 43d						1								
1	compar						1								
1	ed to						1								
1	dose 2						1								
15 EP	30002				15 EP						+ +		7 5 8		Showard
43 FN					43 FN		1								Shewalu [40]
1	1	1	1	1	1	1	1	1	1	1		1			1781

#### 182 Figure 1

#### 183 PRISMA flowchart for the current study.



186 Simplified representation of the evolution of nAb-based therapeutics along the course of a pandemic.

187





# 189 References

190	1.	Yeh, TY.; Contreras, G.P. Tajima D test accurately forecasts Omicron / COVID-19 outbreak.
191		<b>2021</b> , 10.1101/2021.12.02.21267185 %J medRxiv, 2021.2012.2002.21267185,
192		doi:10.1101/2021.12.02.21267185 %J medRxiv.
193	2.	Ahmed, S.F.; Quadeer, A.A.; McKay, M. SARS-CoV-2 T cell responses are expected to remain
194		robust against Omicron. <b>2021</b> , 10.1101/2021.12.12.472315 %J bioRxiv,
195		2021.2012.2012.472315, doi:10.1101/2021.12.12.472315 %J bioRxiv.
196	3.	Bernasconi, A.; Pinoli, P.; Al Khalaf, R.; Alfonsi, T.; Canakoglu, A.; Cilibrasi, L.; Ceri, S. Report
197		on Omicron Spike mutations on epitopes and immunological/epidemiological/kinetics
198		effects from literature. Availabe online: https://virological.org/t/report-on-omicron-spike-
199		mutations-on-epitopes-and-immunological-epidemiological-kinetics-effects-from-
200		literature/770 (accessed on
201	4.	Wilhelm, A.; Widera, M.; Grikscheit, K.; Toptan, T.; Schenk, B.; Pallas, C.; Metzler, M.;
202		Kohmer, N.: Hoehl, S.: Helfritz, F.A., et al. Reduced Neutralization of SARS-CoV-2 Omicron
203		Variant by Vaccine Sera and monoclonal antibodies <b>2021</b> 10 1101/2021 12 07 21267432 %
204		medRxiv 2021 2012 2007 21267432 doi:10.1101/2021 12.07 21267432 %I medRxiv
205	5	Cao Y R Wang I lian F Xiao T Song W Yisimayi A Huang W Li O Wang P An
205	5.	B et al B 1 1 529 escapes the majority of SARS-CoV-2 neutralizing antibodies of diverse
200		epitones <b>2021</b> 10 1101/2021 12 07 470392 %I bioRviv 2021 2012 2007 470392
207		doi:10.1101/2021.12.07.470392 %I bioRxiv
200	6	Color St. Jackson J.; Khan K.; Khoury, D.S.; Moyo Gwoto T.; Togally, H.; Schooners, C.;
205	0.	Amoako D: Karim E: Bornstoin M. et al SARS CoV 2 Omicron has avtensive but
210		incomplete escape of Pfizer PNT162b2 elicited neutralization and requires ACE2 for
211		information <b>2021</b> 10 1101/2021 12 09 21267417 % I modevire 2021 2012 2009 21267417
212		Infection. <b>2021</b> , 10.1101/2021.12.08.2120/417 /0 meuRXIV, 2021.2012.2008.2120/417,
213	7	dol:10.1101/2021.12.08.2126/41/ %J medRXIV.
214	7.	Lu, L.; Mok, B.; Chen, L.; Chan, J.; Tsang, O.; Lam, B.; Chuang, V.; Chu, A.; Chan, A.; Ip, J., et al.
215		Neutralization of SARS-CoV-2 Umicron variant by sera from BN1162b2 of Coronavac vaccine
215		recipients. <b>2021</b> , 10.1101/2021.12.13.21267668 %J medRXIV, 2021.2012.2013.21267668,
21/		doi:10.1101/2021.12.13.21267668 %J medRxiv.
218	8.	Ikemura, N.; Hoshino, A.; Higuchi, Y.; Taminishi, S.; Inaba, T.; Matoba, S. SARS-CoV-2
219		Omicron variant escapes neutralization by vaccinated and convalescent sera and therapeutic
220		monoclonal antibodies. <b>2021</b> , 10.1101/2021.12.13.21267761 %J medRxiv,
221	_	2021.2012.2013.21267761, doi:10.1101/2021.12.13.21267761 %J medRxiv.
222	9.	Basile, K.; Rockett, R.J.; McPhie, K.; Fennell, M.; Johnson-Mackinnon, J.; Agius, J.; Fong, W.;
223		Rahman, H.; Ko, D.; Donavan, L., et al. Improved neutralization of the SARS-CoV-2 Omicron
224		variant after Pfizer-BioNTech BNT162b2 COVID-19 vaccine boosting. <b>2021</b> ,
225		10.1101/2021.12.12.472252 %J bioRxiv, 2021.2012.2012.472252,
226		doi:10.1101/2021.12.12.472252 %J bioRxiv.
227	10.	Garcia-Beltran, W.F.; St Denis, K.J.; Hoelzemer, A.; Lam, E.C.; Nitido, A.D.; Sheehan, M.L.;
228		Berrios, C.; Ofoman, O.; Chang, C.C.; Hauser, B.M., et al. mRNA-based COVID-19 vaccine
229		boosters induce neutralizing immunity against SARS-CoV-2 Omicron variant. <b>2021</b> ,
230		10.1101/2021.12.14.21267755 %J medRxiv, 2021.2012.2014.21267755,
231		doi:10.1101/2021.12.14.21267755 %J medRxiv.
232	11.	Schubert, M.; Bertoglio, F.; Steinke, S.; Heine, P.A.; Ynga-Durand, M.A.; Zuo, F.; Du, L.; Korn,
233		J.; Milosevic, M.; Wenzel, E.V., et al. Human serum from SARS-CoV-2 vaccinated and COVID-
234		19 patients shows reduced binding to the RBD of SARS-CoV-2 Omicron variant in comparison
235		to the original Wuhan strain and the Beta and Delta variants. <b>2021</b> ,
236		10.1101/2021.12.10.21267523 %J medRxiv, 2021.2012.2010.21267523,
237		doi:10.1101/2021.12.10.21267523 %J medRxiv.
238	12.	Planas, D.; Saunders, N.; Maes, P.; Benhassine, F.G.; Planchais, C.; Porrot, F.; Staropoli, I.;
239		Lemoine, F.; Pere, H.; Veyer, D., et al. Considerable escape of SARS-CoV-2 variant Omicron to

240		antibody neutralization. <b>2021</b> , 10.1101/2021.12.14.472630 %J bioRxiv,
241		2021.2012.2014.472630, doi:10.1101/2021.12.14.472630 %J bioRxiv.
242	13.	Liu, L.; Iketani, S.; Guo, Y.; Chan, J.FW.; Wang, M.; Liu, L.; Luo, Y.; Chu, H.; Huang, Y.; Nair,
243		M.S., et al. Striking Antibody Evasion Manifested by the Omicron Variant of SARS-CoV-2.
244		<b>2021</b> , 10.1101/2021.12.14.472719 %J bioRxiv, 2021.2012.2014.472719,
245		doi:10.1101/2021.12.14.472719 %J bioRxiv.
246 247	14.	Aggarwal, A.; Ospina Stella, A.; Walker, G.; Akerman, A.; Milogiannakis, V.; Hoppe, A.C.; Mathiyanan, V.: Fichter, C.: McAllery, S.: Amatayakul-Chantler, S., et al. SARS-CoV-2
248		Omicron: reduction of notent humoral responses and resistance to clinical
249		immunotheraneutics relative to viral variants of concern <b>2021</b>
250		10 1101/2021 12 14 21267772 %I medRxiv_2021 2012 2014 21267772
251		doi:10.1101/2021.12.14.21267772.%L medRxiv
252	15	Rössler A · Rienler I · Bante D · Laer D v · Kimpel I SARS-CoV-2 B 1 1 529 variant
253	101	(Omicron) evades neutralization by sera from vaccinated and convalescent individuals <b>2021</b>
257		10 1101/2021 12 08 21267/91 %L medRxiv 2021 2012 2008 21267/91
255		doi:10.1101/2021.12.08.21267491./// medRviv
255	16	Deinirattisai W Shaw RH Sunasa P Liu C Stuart A S Pollard A L Liu X Lambe T
257	10.	Crook D: Stuart DL et al Reduced neutralisation of SARS-COV-2 Omicron-B 1 1 529
257		variant by post immunication sorum <b>2021</b> 10 1101/2021 12 10 21267534 %L modPriv
250		2021 2012 2010 21267524 doi:10.1101/2021.12.10.21267534 %1 modPviv
255	17	Cong. 7 : Evans, L.D.: Ou, D.: Earaono, L.: Zhang, V. M.: Carlin, C.: Bednash, L.S.: Zhou, T.:
200	17.	Lozanski, G.: Mallampalli, P., et al. Noutralization and Stability of SARS CoV 2 Omicron
201		Variant <b>2021</b> 10 1101/2021 12 16 472024 %I bioPxiv 2021 2012 2016 472024
202		doi:10.1101/2021.12.16.472024.9/1 bioPyin
203	10	Showard D.L. Kim C. Ehling P.A. Bankow A. Castro Donico V. Martin D.B. Poddy S.T.
204	10.	Dillogra L: Karlsson Hodoctam, G. R.: Albort, L. et al. Variable loss of antibody notancy against
205		SARS CoV 2 R 1 1 E20 (Omigran) <b>2021</b> 10 1101/2021 12 10 4722E4 %L bioDviv
200		2021 2012 2010 4722E4 doi:10.1101/2021.12.10.4722E4 V bioDviv
207	10	Jacobson H. Strongort M. Maass H. Ynga Durand M.A. Kossol R. Harrios M. Pand H.
200	19.	Jacobsell, H., Strengert, M., Maass, H., Higa Duranu, M.A., Ressel, D., Harries, M., Kanu, O.,
203		CoV/2 Omigron VoC after mPNA ervector based COVID 19 vaccinations <b>2021</b>
270		10 1101/2021 12 21 21267808 %L modPriv 2021 2012 2021 21267808
271		doi:10.1101/2021.12.21.21207838 /0 meurally, 2021.2012.2021.21207838,
272	20	VanBlargan I. A. : Errica I. M. : Halfmann D. : Zast S. L.: Crowa I. E.: Dursell, I. A.: Kawaaka V.
273	20.	Corti D: Fromont DH: Diamond M. An infectious SAPS CoV 2 P.1.1.520 Omicron virus
274		contr, D., Fremont, D.H., Diamond, W. An infectious SARS-Cov-2 B.1.1.529 Official virus
275		10,1101/2021,12,15,472020,001 his print 2021,2012,2015,472020
270		10.1101/2021.12.13.472020 /0 $100000, 2021.2012.2013.472020,$
277	21	Carrana IM: Alshammany H: Tshaqu I: Singh G: Paskin A: Kawahata H: Saminsky I:
270	21.	Carreno, J.M., Alshammary, H., Tcheou, J., Shigh, G., Kaskin, A., Kawabata, H., Sommsky, L.,
275		a B 1 1 520 variant SABS CoV 2 isolato <b>2021</b> 10 1101/2021 12 20 21262124 % I mod Pviv
200		a D.1.1.525 Valiant SAR5-COV-2 Isolate. <b>2021</b> , 10.1101/2021.12.20.21200154 /0 Inteurxiv,
201	22	ZUZIZUZZZUZUZUZUZUZUZUSIS4, UULIU. 1101/ZUZI. 12.20.21200154 /0 Inteutian.
202	22.	Concentrated Injection colution for infusion (2021) Accessed on December 22, 2021 at
203		bttps://www.tzp.gov.ov/citos/default/files/vovudy.pi.pdf
204 205	22	<u>Inteps://www.iga.gov.au/sites/default/mes/xevddy-pr.put</u> .
205	23.	A Chandra S Call M Dranar LL at al DESISTANCE CONFERDING MUTATIONS IN SARS
200 297		A., CHAHUTA, S., GAH, WI., DIAPET, J.L., ELAI. RESISTANCE CONFERRING WOTATIONS IN SARS-
201 200		modPrin, 2021 2012 2018 21267629 doi:10.1101/2021.12.10.2120/028 %J
∠00 200	24	Encori D. Franchini M. Dirofeki L. a. Burnauf T. Danath N. Javar M. J. Casadayall A
289	24.	COVID-19 convalescent plasma and randomized clinical trials: rebuilding confidence by

291 292		explaining failures and finding signals of efficacy. <b>2021</b> , 10.1101/2021.09.07.21263194 %J medRxiv, 2021.2009.2007.21263194, doi:10.1101/2021.09.07.21263194 %J medRxiv.
293	25.	Libster, R.: Pérez Marc, G.: Wappner, D.: Coviello, S.: Bianchi, A.: Braem, V.: Esteban, I.:
294		Caballero, M.T.: Wood, C.: Berrueta, M., et al. Early High-Titer Plasma Therapy to Prevent
295		Severe Covid-19 in Older Adults. N Engl I Med <b>2021</b> , 384, 610-618.
296		doi:10.1056/NEIMoa2033700
297	26	Sullivan D. Gebo K. Shoham S. Bloch F. Lau B. Shenov A. Mosnaim G. Griadek T.
298	20.	Fukuta, Y.; Patel, B., et al. Randomized Controlled Trial of Early Outpatient COVID-19
299		Treatment with High-Titer Convalescent Plasma. medRxiv 2021.
300	27.	Vickers, M.A.; Sariol, A.; Leon, J.; Ehlers, A.; Locher, A.V.; Dubay, K.A.; Collins, L.; Voss, D.;
301		Odle, A.E.; Holida, M., et al. Exponential increase in neutralizing and spike specific antibodies
302		following vaccination of COVID-19 convalescent plasma donors. <i>Transfusion</i> <b>2021</b> , <i>61</i> , 2099-
303		2106, doi:10.1111/trf.16401.
304	28.	Schmidt, F.; Weisblum, Y.; Rutkowska, M.; Poston, D.; Da Silva, J.; Zhang, F.; Bednarski, E.;
305		Cho. A.: Schaefer-Babaiew. D.I.: Gaebler. C., et al. High genetic barrier to SARS-CoV-2
306		polyclonal neutralizing antibody escape <i>Nature</i> <b>2021</b> 10 1038/s41586-021-04005-0
307		doi 10 1038/s41586-021-04005-0
308	29	Germanio CD: Simmons G: Thorbrogger C: Martinelli R: Stone M: Gniadek T: Busch
300	23.	M.P. Vaccination of COVID-19 Convalescent Plasma Donors Increases Binding and
310		Neutralizing Antibodies Against SARS-CoV-2 Variants <b>2021</b> 10 1101/2021 10 28 21265622
311		%L medRviv 2021 2010 2028 21265622 doi:10.1101/2021.10.28.21265622 %L medRviv
312	30	Dolphikova IV: Iliukhina AA: Kovyrshina AV: Kuzina AV: Gushchin VA: Sinjavin AE:
212	50.	Dolzhikova, I.V., hidkinna, A.A., Kovyrshina, A.V., Kuzina, A.V., Gushenin, V.A., Shidoni, A.E.,
515 514		Pochovyi, A.A., Sinulovskaya, E.V., Kuzhetsova, N.A., Megeryan, M.M., et al. Sputnik Light
314 31E		Dooster after sputfik V vaccination induces robust neutralizing antibody response to
210		D.1.1.325 (Officion) SARS-COV-2 Variant. 2021, 10.1101/2021.12.17.21207570 //0 metarxiv,
310 217	21	2021.2012.2017.2126/9/6, doi:10.1101/2021.12.17.2126/9/6 %) medRXIV.
31/	31.	Lechmere, T.; Shell, L.B.; Granam, C.; Seow, J.; Shalim, Z.A.; Charalampous, T.; Alcolea-
318		Medina, A.; Batra, R.; Nebbla, G.; Edgeworth, J.D., et al. Broad neutralization of SARS–Cov–2
319		variants, including omicron, following breakthrough infection with deita in COVID-19
320		vaccinated individuals. <b>2021</b> , 10.1101/2021.12.01.21266982 %J medRxiv,
321		2021.2012.2001.21266982, doi:10.1101/2021.12.01.21266982 %J medRxiv.
322	32.	Khoury, D.S.; Cromer, D.; Reynaldi, A.; Schlub, T.E.; Wheatley, A.K.; Juno, J.A.; Subbarao, K.;
323		Kent, S.J.; Triccas, J.A.; Davenport, M.P. Neutralizing antibody levels are highly predictive of
324		immune protection from symptomatic SARS-CoV-2 infection. <i>Nat Med</i> <b>2021</b> , 27, 1205-1211,
325		doi:10.1038/s41591-021-01377-8.
326	33.	Feng, S.; Phillips, D.J.; White, T.; Sayal, H.; Aley, P.K.; Bibi, S.; Dold, C.; Fuskova, M.; Gilbert,
327		S.C.; Hirsch, I., et al. Correlates of protection against symptomatic and asymptomatic SARS-
328		CoV-2 infection. <i>Nat Med</i> <b>2021</b> , 27, 2032-2040, doi:10.1038/s41591-021-01540-1.
329	34.	Gilbert, P.B.; Montefiori, D.C.; McDermott, A.B.; Fong, Y.; Benkeser, D.; Deng, W.; Zhou, H.;
330		Houchens, C.R.; Martins, K.; Jayashankar, L., et al. Immune correlates analysis of the mRNA-
331		1273 COVID-19 vaccine efficacy clinical trial. <i>Science</i> <b>2021</b> , eab3435.
332	35.	Earle, K.A.; Ambrosino, D.M.; Fiore-Gartland, A.; Goldblatt, D.; Gilbert, P.B.; Siber, G.R.; Dull,
333		P.; Plotkin, S.A. Evidence for antibody as a protective correlate for COVID-19 vaccines.
334		<i>Vaccine</i> <b>2021</b> , <i>39</i> , 4423-4428, doi:10.1016/j.vaccine.2021.05.063.
335	36.	Krutikov, M.; Palmer, T.; Tut, G.; Fuller, C.; Azmi, B.; Giddings, R.; Shrotri, M.; Kaur, N.; Sylla,
336		P.; Lancaster, T., et al. Prevalence and duration of detectable SARS-CoV-2 nucleocapsid
337		antibodies in staff and residents of long-term care facilities over the first year of the
338		pandemic (VIVALDI study): prospective cohort study in England. The Lancet Healthy
339		Longevity <b>2021</b> , <u>https://doi.org/10.1016/S2666-7568(21)00282-8</u> ,
340		doi: <u>https://doi.org/10.1016/S2666-7568(21)00282-8</u> .

341 342 343 344 345	37.	Amjadi, M.F.; Adyniec, R.R.; Gupta, S.; Bashar, S.J.; Mergaert, A.M.; Braun, K.M.; Moreno, G.K.; O'Connor, D.H.; Friedrich, T.C.; Safdar, N., et al. Anti-membrane and anti-spike antibodies are long-lasting and together discriminate between past COVID-19 infection and vaccination. <b>2021</b> , 10.1101/2021.11.02.21265750 %J medRxiv, 2021.2011.2002.21265750, doi:10.1101/2021.11.02.21265750 %J medRxiv.
346 347 348	38.	Klein, S.; Pekosz, A.; Park, HS.; Ursin, R.; Shapiro, J.; Benner, S.; Littlefield, K.; Kumar, S.; Naik, H.M.; Betenbaugh, M., et al. Sex, age, and hospitalization drive antibody responses in a COVID-19 convalescent plasma donor population. Availabe online:
349		https://www.medrxiv.org/content/medrxiv/early/2020/06/28/2020.06.26.20139063.full.pdf
351	39	Eccosi D : Franchini M. Clinical predictors of SARS-CoV-2 neutralizing antibody titers in
352	55.	COVID-19 convalescents: Implications for convalescent plasma donor recruitment. <i>European</i>
353		journal of haematology <b>2021</b> , 107, 24-28, doi:10.1111/ejh.13630.
354	40.	Yu, X.; Wei, D.; Xu, W.; Li, Y.; Li, X.; Zhang, Xx.; Qu, J.; Yang, Z.; Chen, E. Pseudotyped SARS-
355		CoV-2 Omicron variant exhibits significant escape from neutralization induced by a third
356		booster dose of vaccination. <b>2021</b> , 10.1101/2021.12.17.21267961 %J medRxiv,
357		2021.2012.2017.21267961, doi:10.1101/2021.12.17.21267961 %J medRxiv.
358	41.	Zhao, X.; Li, D.; Ruan, W.; Zhang, R.; Zheng, A.; Qiao, S.; Zheng, X.; Zhao, Y.; Chen, Z.; Dai, L.,
359		et al. Reduced sera neutralization to Omicron SARS-CoV-2 by both inactivated and protein
360		subunit vaccines and the convalescents. <b>2021</b> , 10.1101/2021.12.16.472391 %J bioRxiv,
361		2021.2012.2016.472391, doi:10.1101/2021.12.16.472391 %J bioRxiv.
362	42.	Chatterjee, D.; Tauzin, A.; Marchitto, L.; Gong, S.Y.; Boutin, M.; Bourassa, C.; Beaudoin-
363		Bussieres, G.; Bo, Y.; Ding, S.; Laumaea, A., et al. SARS-CoV-2 Omicron Spike recognition by
364		plasma from individuals receiving BNT162b2 mRNA vaccination with a 16-weeks interval
365		between doses. <b>2021</b> , 10.1101/2021.12.21.473679 %J bioRxiv, 2021.2012.2021.473679,
366		doi:10.1101/2021.12.21.473679 %J bioRxiv.
367	43.	Grunau, B.; Goldfarb, D.M.; Asamoah-Boaheng, M.; Golding, L.; Kirkham, T.L.; Demers, P.A.;
368		Lavoie, P.M. Immunogenicity of Extended mRNA SARS-CoV-2 Vaccine Dosing Intervals. Jama
369		<b>2021</b> , 10.1001/jama.2021.21921, doi:10.1001/jama.2021.21921.
370	44.	Tauzin, A.; Nayrac, M.; Benlarbi, M.; Gong, S.Y.; Gasser, R.; Beaudoin-Bussieres, G.; Brassard,
3/1		N.; Laumaea, A.; Vezina, D.; Prevost, J., et al. A single BN1162b2 mRNA dose elicits
372		antibodies with Fc-mediated effector functions and boost pre-existing numoral and T cell
3/3		responses. <i>meakxiv [Preprint]</i> <b>2021</b> , 10.1101/2021.03.18.435972 %J blokxiv,
374	45	2021.2003.2018.435972, doi:10.1101/2021.03.18.435972 %J DioKXIV.
375	45.	Skowronski, D.M.; Setayesngar, S.; Febriani, Y.; Ouakki, M.; Zou, M.; Taibot, D.; Prystajecky,
370		with mixed schedules and extended dosing intervals: test-negative design studies from
378		British Columbia and Quebec Canada <b>2021</b> 10 1101/2021 10 26 21265397 %L medRviv
379		2021 2010 2026 21265397 doi:10 1101/2021 10 26 21265397 %I medRviv
380	46	MRC Centre for Global Infectious Disease Analysis Report 50 - Hospitalisation risk for
381	40.	Omicron cases in England. Accessed online at https://www.imperial.ac.uk/media/imperial-
382		college/medicine/mrc-gida/2021-12-22-COVID19-Report-50 pdf on December 23, 2021
383		Availabe online: (accessed on
384	47.	Wolter, N.: Jassat, W.: Walaza, S.: Welch, R.: Moultrie, H.: Groome, M.: Amoako, D.G.:
385		Everatt, J.: Bhiman, J.N.: Scheepers, C., et al. Early assessment of the clinical severity of the
386		SARS-CoV-2 Omicron variant in South Africa. <b>2021</b> , 10.1101/2021.12.21.21268116 %J
387		medRxiv, 2021.2012.2021.21268116, doi:10.1101/2021.12.21.21268116 %J medRxiv.
388	48.	Gruell, H.; Vanshylla, K.; Tober-Lau, P.; Hillus, D.; Schommers, P.; Lehmann, C.; Kurth, F.;
389		Sander, L.E.; Klein, F. mRNA booster immunization elicits potent neutralizing serum activity
390		against the SARS-CoV-2 Omicron variant. <b>2021</b> , 10.1101/2021.12.14.21267769 %J medRxiv,
391		2021.2012.2014.21267769, doi:10.1101/2021.12.14.21267769 %J medRxiv.

392 393 394 395 396	49.	Hoffmann, M.; Krüger, N.; Schulz, S.; Cossmann, A.; Rocha, C.; Kempf, A.; Nehlmeier, I.; Graichen, L.; Moldenhauer, AS.; Winkler, M.S., et al. The Omicron variant is highly resistant against antibody-mediated neutralization - implications for control of the COVID-19 pandemic. <b>2021</b> , 10.1101/2021.12.12.472286 %J bioRxiv, 2021.2012.2012.472286, doi:10.1101/2021.12.12.472286 %J bioRxiv.
397	50.	Schmidt, F.; Muecksch, F.; Weisblum, Y.; Da Silva, J.; Bednarski, E.; Cho, A.; Wang, Z.;
398		Gaebler, C.; Caskey, M.; Nussenzweig, M., et al. Plasma neutralization properties of the
399		SARS-CoV-2 Omicron variant. <b>2021</b> , 10.1101/2021.12.12.21267646 %J medRxiv,
400	F 1	2021.2012.2012.21267646, doi:10.1101/2021.12.12.21267646 %J medRxiv.
401	51.	znang, L.; Li, Q.; Liang, Z.; Li, T.; Liu, S.; Cui, Q.; Nie, J.; Wu, Q.; Qu, X.; Huang, W., et al. The
402 403		<i>&amp; infections</i> <b>2021</b> 10 1080/22221751 2021 2017757 1-11
404		doi:10.1080/22221751.2021.2017757.
405	52.	Zou, j.; Xia, H.; Xie, X.; Kurhade, C.; Machado, R.R.; Weaver, S.C.; Ren, P.; Shi, PY.
406		Neutralization against Omicron SARS-CoV-2 from previous non-Omicron infection. 2021,
407		10.1101/2021.12.20.473584 %J bioRxiv, 2021.2012.2020.473584,
408		doi:10.1101/2021.12.20.473584 %J bioRxiv.
409	53.	Lusvarghi, S.; Pollett, S.D.; Neerukonda, S.N.; WANG, W.; Wang, R.; Vassell, R.; Epsi, N.J.;
410		Fries, A.C.; Agan, B.K.; Lindholm, D.A., et al. SARS-CoV-2 Omicron neutralization by
411		therapeutic antibodies, convalescent sera, and post-mRNA vaccine booster. 2021,
412		10.1101/2021.12.22.473880 %J bioRxiv, 2021.2012.2022.473880,
413		doi:10.1101/2021.12.22.473880 %J bioRxiv.
414	54.	Syed, A.M.; Ciling, A.; Khalid, M.M.; Sreekumar, B.; Kumar, G.R.; Silva, I.; Milbes, B.; Kojima,
415		N.; Hess, V.; Shacreaw, M., et al. Omicron mutations enhance infectivity and reduce
410		antibody neutralization of SARS-CoV-2 virus-like particles. <b>2021</b> ,
417 /19		10.1101/2021.12.20.21208048 % IneuRxiv, 2021.2012.2020.21208048,
410 419	55	Doria-Rose N · Shen X · Schmidt S D · O'Dell S · McDanal C · Feng W · Tong L · Faton A ·
420	55.	Maglinao M : Tang H et al Booster of mRNA-1273 Vaccine Reduces SARS-CoV-2 Omicron
421		Escape from Neutralizing Antibodies. <b>2021</b> , 10.1101/2021.12.15.21267805 %I medRxiv.
422		2021,2012,2015,21267805, doi:10.1101/2021.12.15.21267805 %J medRxiv.
423	56.	Edara, VV.; Manning, K.E.; Ellis, M.; Lai, L.; Moore, K.M.; Foster, S.L.; Floyd, K.; Davis-
424		Gardner, M.E.; Mantus, G.; Nyhoff, L.E., et al. mRNA-1273 and BNT162b2 mRNA vaccines
425		have reduced neutralizing activity against the SARS-CoV-2 Omicron variant. <b>2021</b> ,
426		10.1101/2021.12.20.473557 %J bioRxiv, 2021.2012.2020.473557,
427		doi:10.1101/2021.12.20.473557 %J bioRxiv.